menu
    • menu
    [{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Xanamem

    Menu

    Xanamem

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actinogen Randomizes First US Participant in XanaMIA Phase 2b/3 Alzheimer's Disease Trial

                            Details : Xanamem (UE2343) blocks the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for the treatment of Alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2024

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actinogen announces Further Positive Results on Depression in the XanCIDD Phase 2a Trial

                            Details : Xanamem (UE2343) blocks the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for the treatment of major depressive disorder.

                            Product Name : Xanamem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2024

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actinogen’s Xanamem® Shows Superiority in Depression in Phase 2a XanaCIDD Trial

                            Details : Xanamem (UE2343) blocks the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for the treatment of major depressive disorder.

                            Product Name : Xanamem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial

                            Details : Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for major depressive disorder.

                            Product Name : Xanamem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2024

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Treated in Actinogen's XanaMIA Phase 2b Alzheimer's Disease Trial

                            Details : Xanamem inhibits cortisol production in the brain by targeting the 11β-HSD1 enzyme, designed to enter the brain after intestinal absorption.

                            Product Name : Xanamem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actinogen Optimizes XanaMIA Phase 2b Alzheimer's Disease Trial Design and Provides General Business Update

                            Details : Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing.

                            Product Name : Xanamem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA agrees to Actinogen Six-month Phase 2b Alzheimer's Disease trial

                            Details : Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer's Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future.

                            Product Name : UE2343

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 22, 2022

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Actinogen

                            Australia arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actinogen Announces First Patient Treated In Depression And Cognitive Impairment Phase 2 Clinical Trial

                            Details : Xanamem has the potential to be an effective low-dose daily oral therapy for the treatment of depression, Alzheimer's Disease and many other neurological conditions where it may be used alone or in combination with other treatments.

                            Product Name : Xanamem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2022

                            Lead Product(s) : Xanamem

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth